Anchiano Therapeutics Ltd. (ANCN) expects to raise $35 million in an initial public offering on Tuesday, February 12th, IPO Scoop reports. The company plans to issue 2,400,000 shares at $14.55 per share.
Anchiano Therapeutics Ltd. has a market cap of $95.6 million.
Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.
Anchiano Therapeutics Ltd. provided the following description of their company for its IPO: “(Note: (Public offering) “Our ordinary shares are listed on the Tel Aviv Stock Exchange Ltd., or the TASE, under the symbol “ANCN.” On January 28, 2019, the last reported sale price of our ordinary shares on the TASE was NIS 10.72, or $2.91 per ordinary share (based on the exchange rate reported by the Bank of Israel on that date, which was NIS 3.680 = $1.00). Based on the last reported sale price of our ordinary shares on the TASE on January 28, 2019, we have assumed an initial public offering price of $14.55 per ADS. “ We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard of care for early-stage bladder cancer. We have discovered and are developing a biologic agent, inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in effectiveness and problematic in toxicity. “.
Anchiano Therapeutics Ltd. was founded in 2011 and has 17 employees. The company is located at 1/3 High-Tech Village, Givat Ram, P.O. Box 39264 Jerusalem, 9139102 Israel and can be reached via phone at +972 (2) 548-6555 or on the web at http://www.anchiano.com.
Receive News & Ratings for Anchiano Therapeutics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anchiano Therapeutics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.